■探讨重组人血管内皮抑素注射液(名为Endo)与抗PD-1联合治疗80岁及以上老年非小细胞肺癌(NSCLC)的疗效和安全性。
■巢湖医院呼吸与重症医学科收治的181例80岁及以上非小细胞肺癌患者的回顾性分析,安徽医科大学附属,从2019年6月到2024年1月。基于纳入标准,纳入接受至少一个周期的Endo与抗PD-1联合治疗的患者。收集临床和病理资料,包括全血细胞计数,肝肾功能,心电图,凝血功能,甲状腺功能,心肌酶,和全身成像。在2024年1月25日的最后随访中记录了不良事件。主要终点是无进展生存期(PFS)和总生存期(OS),以安全为次要终点。
■本研究涉及14例80岁以上的老年非小细胞肺癌患者。中位无进展生存期(mPFS)为102天,中位总生存期(mOS)为311天。基于治疗周期的亚组分析显示,长期组的441天mPFS无显著增加(≥6个周期,5名患者)与短期组(<6个周期,9名患者)。然而,长期组的mOS显著超过短期组141天,具有统计学意义(P=0.048)。进一步分类显示,与联合维持组(Endo联合免疫,441天)。单药治疗维持组的mOS(686天)比联合治疗维持组(311天)更长,但无统计学意义(P=0.710、0.920)。在整个治疗过程中,记录77起不良事件,主要为1-2级,没有新的治疗相关反应发生。总的来说,Endo联合抗PD-1的安全性被认为是良好且可控的.
■对于80岁及以上的非小细胞肺癌患者,Endo和抗PD-1的联合治疗可能是一种有效的治疗选择。
UNASSIGNED: To investigate the efficacy and safety of combining Recombinant Human Endostatin Injection (marketed as Endo) with anti-PD-1 in elderly patients aged 80 and above with non-small cell lung cancer (NSCLC).
UNASSIGNED: Retrospective analysis of 181 patients with NSCLC aged 80 and above treated in the Department of Respiratory and Critical Care Medicine at Chaohu Hospital, affiliated with Anhui Medical University, from June 2019 to January 2024. Patients who received at least one cycle of combined Endo with anti-PD-1 were included based on inclusion criteria. Clinical and pathological data were collected, including complete blood count, liver and kidney function, electrocardiogram, coagulation function, thyroid function, cardiac enzymes, and whole-body imaging. Adverse events were recorded with a final follow-up on January 25, 2024. The primary endpoints were progression-free survival (PFS) and overall survival (OS), with safety as a secondary endpoint.
UNASSIGNED: This study involved 14 elderly patients with NSCLC aged over 80. Median progression-free survival (mPFS) was 102 days, and median overall survival (mOS) was 311 days. Subgroup analyses based on treatment cycles showed a non-significant 441-day mPFS increase in the long-term group (≥6 cycles, 5 patients) compared to the short-term group (<6 cycles, 9 patients). However, the mOS in the long-term group significantly exceeded the short-term group by 141 days, with statistical significance (P=0.048). Further categorization revealed a 204-day shorter mPFS in the monotherapy maintenance group (Endo or Immunol) compared to the combination maintenance group (Endo combined with Immunol, 441 days). The mOS of the monotherapy maintenance group was longer (686 days) than the combination maintenance group (311 days), but no statistical significance (P= 0.710, 0.920). Throughout the treatment, 77 adverse events were recorded, mainly grade 1-2, with no new treatment-related reactions occurred. Overall, the safety of Endo combined with anti-PD-1 was considered good and manageable.
UNASSIGNED: The combination of Endo and anti-PD-1 could be an effective treatment choice for patients with NSCLC aged 80 and above.